BUFFALO BIOLABS, LLC

Company Information

Company Name
BUFFALO BIOLABS, LLC
Address
73 HIGH ST
BUFFALO, NY, 14203-0000
Phone
n/a
URL
http://www.buffalobiolabs.com
DUNS
830459546
Number of Employees
31

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$663,716.00
4
SBIR Phase II
$1,496,764.00
1
STTR Phase I
$504,608.00
3
Chart code to be here

Award List

  1. Targeting MLL As Anticancer Therapy for Infant Acute Lymphoblastic Leukemia

    Amount: $130,694.00

    DESCRIPTION (provided by applicant): Advances in treatment strategies have increased the long-term survival of children with acute lymphoblastic leukemia (ALL). However, the outlook of infants with AL ...

    SBIR Phase I 2009 Department of Health and Human Services
  2. Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy

    Amount: $104,608.00

    DESCRIPTION (provided by applicant): One of the major problems in the fight against cancer is the intrinsic or acquired resistance of tumors to current cancer treatments, particularly that associated ...

    STTR Phase I 2009 Department of Health and Human Services
  3. Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5

    Amount: $109,719.00

    DESCRIPTION (provided by applicant): Systemic treatment with the bacterial flagellin protein, a Toll-like receptor 5 (TLR5) agonist, provides protection against high dose radiation through activation ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. TAS::75 0849::TAS SBIR TOPIC 255 PHASE II DEVELOPMENT OF ANTICANCER AGENTS

    Amount: $1,496,764.00

    Aberrant functioning of proteins within stress response pathways (e.g. p53, NF-B, heat shock response) are prominent features in many cancer types. Such alterations have been associated with poor resp ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. Suv39H Targeted Therapy for Treatment of Childhood Rhabdomyosarcoma

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is a childhood malignant tumor and is thought to arise due to the arrest of skeletal muscle differentiation (myogenesis) program. It account ...

    STTR Phase I 2012 Department of Health and Human Services
  6. Testing of novel anti-cancer compounds Curaxins against pancreatic cancer

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Mortality from pancreatic ductal adenocarcinoma (PDA) is close to 100% due to the absence of effective treatment approaches. This proposal is focused on determini ...

    STTR Phase I 2012 Department of Health and Human Services
  7. IGF::OT::IGF OTHER FUNCTIONS RandD- MEDICAL BIOMEDICAL (BASIC RESEARCH)

    Amount: $200,000.00

    Head and neck (HandN) cancer is recognized as a significant threat to public health and a substantial economic challenge. The efficacy of radiotherapy widely used to treat HandN cancer is limited by s ...

    SBIR Phase I 2012 Department of Health and Human Services
  8. Deimmunized TLR5 Agonist for Anticancer Therapy

    Amount: $223,303.00

    ABSTRACT: Radiotherapy is widely used to treat various types of cancer; however, its effectiveness is frequently limited by severe adverse effects resulting from radiation-induced damage to normal tis ...

    SBIR Phase I 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government